The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos (Q50607584)

16 March 2018

title

The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos (English)

1 reference

16 March 2018

World Health Organization

main subject

1 reference

1

Ayalew Tefferi

1 reference

16 March 2018

3

James W Vardiman

1 reference

16 March 2018

author name string

Juergen Thiele

series ordinal

2

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 September 2009

1 reference

16 March 2018

published in

Cancer

1 reference

16 March 2018

volume

115

1 reference

16 March 2018

issue

17

1 reference

16 March 2018

page(s)

3842-3847

1 reference

16 March 2018

Oncogenes in myeloproliferative disorders

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The saga of JAK2 mutations and translocations in hematologic disorders: pathogenesis, diagnostic and therapeutic prospects, and revised World Health Organization diagnostic criteria for myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The history of myeloproliferative disorders: before and after Dameshek

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Eosinophilia: secondary, clonal and idiopathic

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Clonal development of myeloproliferative disorders: clues to hematopoietic differentiation and multistep pathogenesis of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The severity of FIP1L1-PDGFRA-positive chronic eosinophilic leukaemia is associated with polymorphic variation at the IL5RA locus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Classification of Ph-negative chronic myeloproliferative disorders--morphology as the yardstick of classification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The JAK2 V617F mutation is rare in RARS but common in RARS-T

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Should a platelet limit of 600 x 109/l be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24440

7 January 2021

Identifiers

DOI

10.1002/CNCR.24440

1 reference

16 March 2018

1 reference

16 March 2018